Galien Golden Jubilee Forum USA 2021

Oct. 28th, 2021
12PM – 1:15PM

In-person registrationLive broadcast registration

Sue Desmond-Hellmann, Prix Galien Committee Chair, Galien Forum Co-Chair & Former CEO, Bill & Melinda Gates Foundation
Petra Jantzer, PhD, Senior Managing Director – Life Sciences, Europe, Accenture

Stéphane Bancel, CEO, Moderna
Albert Bourla, Chairman & CEO, Pfizer
Pam Cheng, Executive Vice-President, Operations and Information Technology, AstraZeneca
Alex Gorsky, Chairman, Board of Directors & CEO, Johnson & Johnson
Leonard Schleifer, Founder, President & CEO, Regeneron
Daniel M. Skovronsky, President Lilly Research Laboratories, Chief Scientific & Medical Officer, Eli Lilly and Company


Sue Desmond-Hellmann
Prix Galien Committee Chair; Galien Forum Co-Chair;
Former CEO, Bill & Melinda Gates Foundation

Susan D. Desmond-Hellmann is a physician scientist who has spent the past four decades as an innovator and leader in life sciences. Dr. Desmond-Hellmann most recently served as the Chief Executive Officer of Bill & Melinda Gates Foundation, stepping down in January 2020 to become Senior Advisor and Board Member of the Gates Medical Research Institute. She joined the Board of Directors of Pfizer April, 2020, and began serving as Senior Advisor Google Ventures in May 2020. She has served as a Senior Advisor at BDT Capital, LLC, a private investment firm, since October, 2017. Prior to joining The Gates Foundation in May 2014, she was the Chancellor at University of California, San Francisco (UCSF) 2009-2014 where she remains an Adjunct Professor. From 2004 through 2009, Dr. Desmond-Hellmann served as President of Product Development at Genentech, where she was responsible for pre-clinical and clinical development, business development, and product portfolio management. She joined Genentech in 1995. Prior to joining Genentech, Dr. Desmond-Hellmann was associate director of clinical cancer research at Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Desmond-Hellmann previously served as a member of the board of directors of Facebook 2013-2019 and The Procter & Gamble Company 2010-2016. Dr. Desmond-Hellmann holds a B.S. in Pre-Med and an M.D. from the University of Nevada, Reno, and an M.P.H. from the University of California, Berkeley. She is board certified in Internal Medicine and Medical Oncology.

Petra Jantzer, PhD
Senior Managing Director – Life Sciences, Europe

Petra Jantzer leads Accenture’s European Life Sciences Business and is the Account CEO for one of our largest global Pharmaceutical clients worldwide. Her professional roots are in basic science, empowering her with the experience to also oversee Accenture’s European Life Sciences Research & Development Business. Petra’s mission is to support global Life Science Leaders in bringing innovative medicines to patients and ultimately achieve better health outcomes.

Dr. Jantzer has more than 20 years’ experience in the bio-pharmaceuticals sector, both as an advisor and as a researcher. She has profound industry and R&D knowledge (holding a PhD in immunology and an honors degree in molecular biology), deep business process understanding, and more than a decade of C-level counseling experience to help clients (digitally) transform their businesses.

Petra believes that diversity is critical to the success of companies, economies, and societies.  This belief motivated her to co-found “Advance – gender equality in business”, a cross-industry association of 120+ mostly blue-chip company members in Switzerland with a joint mission. She is honored to represent Switzerland in the G20 EMPOWER initiative to drive gender-equality globally.

Petra is a passionate people developer and firmly believes that leaders need to nurture the next generation of leadership to be better than the one before it. During her career, she has been a role model for gender equality in the workplace and beyond and is viewed as a strong force in fostering talent – both male and female.

Stéphane Bancel

Stéphane Bancel has served as Moderna’s Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancelserved as Asia-Pacific Sales and Marketing Director for bioMérieux.

Mr. Bancel currently serves on the board of directors of Qiagen N.V. and Indigo. He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an MBA from Harvard Business School.

Albert Bourla
Chairman & CEO

Dr. Albert Bourla is Chairman and CEO of Pfizer. Before becoming CEO, he was COO, overseeing commercial strategy, manufacturing, and global product development. Previously, he was group president of Pfizer Innovative Health, including Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. He also created the Patient and Health Impact group, dedicated to increasing patient access, demonstrating the value of Pfizer’s medicines, and business model innovation. Prior, he was president of Established Products business. He is a Doctor of Veterinary Medicine and joined Pfizer in 1993 in the Animal Health division. In 2020, Dr. Bourla was ranked America’s top CEO in the pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of the Partnership for New York City, a trustee of the US Council for International Business, and a director on multiple boards, including Pfizer Inc., the Pfizer Foundation, PhRMA, and Catalyst.

Pam Cheng
Executive Vice-President, Operations and Information Technology

Skills and experience: Pam joined AstraZeneca in June 2015 after having spent 18 years with Merck/MSD in Global Manufacturing and Supply Chain and Commercial roles. Pam was the Head of Global Supply Chain Management & Logistics for Merck and led the transformation of Merck supply chains across the global supply network. Pam also held the role of President of MSD China, responsible for MSD’s entire business in China. Prior to joining Merck, Pam held various engineering and project management positions at Universal Oil Products, Union Carbide Corporation and GAF Chemicals. Pam holds Bachelor’s and Master’s degrees in chemical engineering from Stevens Institute of Technology in New Jersey and an MBA in marketing from Pace University in New York. In addition to her role at AstraZeneca, Pam serves as a Non-Executive Director of the Smiths Group plc Board. Pam also serves as an Advisor to the International Society of Pharmaceutical Engineering (ISPE) Board of Directors.

Alex Gorsky
Chairman, Board of Directors & CEO
Johnson & Johnson

Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson. Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next three decades, he advanced through positions of increasing responsibility in sales, marketing, and management, culminating in being named CEO and Chairman in 2012. Under Alex’s leadership, Johnson & Johnson continues to be one of the world’s exceptional corporations, and is currently the number one pharmaceutical company on Fortune magazine’s list of the ‘World’s Most Admired Companies.’

Alex is an active member of the Business Roundtable and the Business Council, and sits on the board of directors of the Travis Manion Foundation and IBM.

Alex graduated from the U.S. Military Academy at West Point, NY, and served six years in the Army. He earned his MBA from the Wharton School of the University of Pennsylvania in 1996.

Leonard Schleifer
Founder, President & CEO

Leonard S. Schleifer, M.D., Ph.D., founded Regeneron in 1988, and has been President, Chief Executive Officer and a Director since its inception. Len, together with President and Chief Scientific Officer George Yancopoulos, M.D., Ph.D., has built the company from a tiny startup into one of the world’s leading biotechnology companies, with a unique science-driven culture. With 2020 revenue of $8.5 billion, Len continues to guide Regeneron’s strong growth through an increasingly diversified portfolio of innovative medicines. Len has been recognized as a 2020 Businessperson of the Year by Fortune, one of Barron’s Best CEOs, a Yale SOM Legend in Leadership and as E&Y’s Life Sciences Entrepreneur of the Year. He was also recently awarded the Walter Reed Distinguished Service Award and the Business Council of Westchester’s Global Leadership Laureate Award along with Dr. Yancopoulos, and was listed on Crain’s New York Business Notable in Health Care List. Under his leadership, Regeneron has been repeatedly voted a top company to work for in the biopharmaceutical industry by Science magazine, has been consistently ranked a most innovative company by Forbes and been acknowledged for its commitment to corporate responsibility by Newsweek and Forbes JUST 100, among others. Over the past year, Regeneron has also been recognized for its pandemic response by organizations including Fast Company’s World Changing Ideas.

Len graduated Phi Beta Kappa and summa cum laude from Cornell University and earned his M.D. and Ph.D. in Pharmacology from the University of Virginia. He is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology. In 2019, he was elected as a Fellow by American Association for the Advancement of Science (AAAS).

Daniel M. Skovronsky
President Lilly Research Laboratories
Chief Scientific & Medical Officer

Eli Lilly and Company

Dan Skovronsky is the chief scientific and medical officer of Eli Lilly and Company and president of Lilly Research Laboratories. He also has responsibility for global business development.
Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics, vice president diabetes research, and most recently, senior vice president, clinical and product development. Dan has been closely involved in progress across all of Lilly’s therapeutic areas, including leading the recent acquisitions of Loxo Oncology and Prevail Therapeutics, the development of Lilly’s anti-COVID monoclonal antibodies, and Lilly’s progress in Alzheimer’s disease.

Dan is a neuroscientist and neuropathologist, having completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994.